FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4255853164> ?p ?o ?g. }

• W4255853164 endingPage "A220" @default.
• W4255853164 startingPage "A220.1" @default.
• W4255853164 abstract "<h3>Background</h3> Biological therapy has dramatically improved the treatment of rheumatoid arthritis (RA). One-third of patients however show a lack of clinical response to this treatment. The use of robust predictive markers of response to identify individuals who are likely to respond to biological treatments may provide guidance in optimizing treatment strategies and lead to lower costs. <h3>Objectives</h3> To test the ability of MRP8/14 serum complexes, a major granulocyte and monocyte protein associated with inflammation in patients with RA¹, to differentiate between responders and non-responders to various biological treatments and to monitor disease activity in these RA patients. <h3>Methods</h3> 170 RA patients were treated with adalimumab, infliximab or rituximab and were categorized into responders (n= 123) and non-responders (n = 47) according to the European League Against Rheumatism (EULAR) response criteria. Serum concentrations of MRP8/14 complexes were measured at baseline, week 4 and week 16 and divided in low and high MRP8/14 serum complexes level groups based on the median level for each treatment group. Non-parametric tests were used to analyse the data. <h3>Results</h3> Before initiation of adalimumab, infliximab or rituximab treatment, responders showed significantly higher levels of MRP8/14 serum complexes compared to non-responders. (p=0.010, p=0.001 and p<0.001, respectively). Logistic regression analysis showed that having a high level of MRP8/14 serum complexes at baseline increased the odds of being a responder by a factor of 3.3 till 55. MRP8/14 serum complexes levels decreased after 4 weeks with respectively 46% and 60% (respectively median delta changes Δ400;IQ 160-895 and 840;IQ170-1170) and 16 weeks with 61% and 68% (Δ730;IQ220-1120 and Δ970;IQ530-1830) of treatment in responders to adalimumab and infliximab, while MRP8/14 serum complexes levels were stable in non-responders. In patients treated with rituximab, MRP8/14 serum complexes decreased with 61% (Δ1670;IQ959.5-3520) after 16 weeks in responders (p = 0.0005) and increased with 89% (Δ960;IQ405-1135) after 16 weeks in non-responders to treatment (p = 0.0039). <h3>Conclusions</h3> MRP8/14 serum complexes can be used as a biomarker predictive of the response to biological therapy in RA patients. <h3>References</h3> Chen YS, Yan W, Geczy CL, Brown MA, Thomas R. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. <i>Arthritis Res Ther</i> 2009;<b>11</b>:R39. <h3>Disclosure of Interest</h3> None Declared" @default.
• W4255853164 created "2022-05-12" @default.
• W4255853164 creator A5021685324 @default.
• W4255853164 creator A5028502338 @default.
• W4255853164 creator A5061179734 @default.
• W4255853164 creator A5066716373 @default.
• W4255853164 creator A5082114687 @default.
• W4255853164 creator A5085622358 @default.
• W4255853164 creator A5086779853 @default.
• W4255853164 creator A5086904782 @default.
• W4255853164 creator A5091438165 @default.
• W4255853164 date "2013-06-01" @default.
• W4255853164 modified "2023-09-26" @default.
• W4255853164 title "THU0167 MRP8/14 Serum Complexes as Predictor of Response to Biological Treatments in Rheumatoid Arthritis" @default.
• W4255853164 doi "https://doi.org/10.1136/annrheumdis-2013-eular.695" @default.
• W4255853164 hasPublicationYear "2013" @default.
• W4255853164 type Work @default.
• W4255853164 citedByCount "1" @default.
• W4255853164 countsByYear W42558531642016 @default.
• W4255853164 crossrefType "journal-article" @default.
• W4255853164 hasAuthorship W4255853164A5021685324 @default.
• W4255853164 hasAuthorship W4255853164A5028502338 @default.
• W4255853164 hasAuthorship W4255853164A5061179734 @default.
• W4255853164 hasAuthorship W4255853164A5066716373 @default.
• W4255853164 hasAuthorship W4255853164A5082114687 @default.
• W4255853164 hasAuthorship W4255853164A5085622358 @default.
• W4255853164 hasAuthorship W4255853164A5086779853 @default.
• W4255853164 hasAuthorship W4255853164A5086904782 @default.
• W4255853164 hasAuthorship W4255853164A5091438165 @default.
• W4255853164 hasConcept C126322002 @default.
• W4255853164 hasConcept C151956035 @default.
• W4255853164 hasConcept C17991360 @default.
• W4255853164 hasConcept C198451711 @default.
• W4255853164 hasConcept C203014093 @default.
• W4255853164 hasConcept C2777138892 @default.
• W4255853164 hasConcept C2777489490 @default.
• W4255853164 hasConcept C2777575956 @default.
• W4255853164 hasConcept C2779338263 @default.
• W4255853164 hasConcept C2780132546 @default.
• W4255853164 hasConcept C2780653079 @default.
• W4255853164 hasConcept C71924100 @default.
• W4255853164 hasConcept C90924648 @default.
• W4255853164 hasConceptScore W4255853164C126322002 @default.
• W4255853164 hasConceptScore W4255853164C151956035 @default.
• W4255853164 hasConceptScore W4255853164C17991360 @default.
• W4255853164 hasConceptScore W4255853164C198451711 @default.
• W4255853164 hasConceptScore W4255853164C203014093 @default.
• W4255853164 hasConceptScore W4255853164C2777138892 @default.
• W4255853164 hasConceptScore W4255853164C2777489490 @default.
• W4255853164 hasConceptScore W4255853164C2777575956 @default.
• W4255853164 hasConceptScore W4255853164C2779338263 @default.
• W4255853164 hasConceptScore W4255853164C2780132546 @default.
• W4255853164 hasConceptScore W4255853164C2780653079 @default.
• W4255853164 hasConceptScore W4255853164C71924100 @default.
• W4255853164 hasConceptScore W4255853164C90924648 @default.
• W4255853164 hasIssue "Suppl 3" @default.
• W4255853164 hasLocation W42558531641 @default.
• W4255853164 hasOpenAccess W4255853164 @default.
• W4255853164 hasPrimaryLocation W42558531641 @default.
• W4255853164 hasRelatedWork W2039662997 @default.
• W4255853164 hasRelatedWork W2054306546 @default.
• W4255853164 hasRelatedWork W2064215099 @default.
• W4255853164 hasRelatedWork W2081987637 @default.
• W4255853164 hasRelatedWork W2119875305 @default.
• W4255853164 hasRelatedWork W2132624379 @default.
• W4255853164 hasRelatedWork W2136821664 @default.
• W4255853164 hasRelatedWork W2909637171 @default.
• W4255853164 hasRelatedWork W4255853164 @default.
• W4255853164 hasRelatedWork W2185923697 @default.
• W4255853164 hasVolume "72" @default.
• W4255853164 isParatext "false" @default.
• W4255853164 isRetracted "false" @default.
• W4255853164 workType "article" @default.